- Home
- PIII vs BLRX Comparison
PIII vs BLRX Comparison
Compare PIII & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- BLRX
- Stock Information
- Founded
- PIII 2015
- BLRX 2003
- Country
- PIII United States
- BLRX Israel
- Employees
- PIII N/A
- BLRX N/A
- Industry
- PIII Medical/Nursing Services
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- PIII Health Care
- BLRX Health Care
- Exchange
- PIII Nasdaq
- BLRX Nasdaq
- Market Cap
- PIII 32.2M
- BLRX 36.0M
- IPO Year
- PIII N/A
- BLRX 2011
- Fundamental
- Price
- PIII $0.20
- BLRX $0.20
- Analyst Decision
- PIII Buy
- BLRX Strong Buy
- Analyst Count
- PIII 3
- BLRX 2
- Target Price
- PIII $2.38
- BLRX $5.50
- AVG Volume (30 Days)
- PIII 347.2K
- BLRX 1.7M
- Earning Date
- PIII 11-12-2024
- BLRX 11-25-2024
- Dividend Yield
- PIII N/A
- BLRX N/A
- EPS Growth
- PIII N/A
- BLRX N/A
- EPS
- PIII N/A
- BLRX N/A
- Revenue
- PIII $1,476,630,000.00
- BLRX $21,991,000.00
- Revenue This Year
- PIII $21.45
- BLRX N/A
- Revenue Next Year
- PIII N/A
- BLRX N/A
- P/E Ratio
- PIII N/A
- BLRX N/A
- Revenue Growth
- PIII 25.38
- BLRX N/A
- 52 Week Low
- PIII $0.18
- BLRX $0.19
- 52 Week High
- PIII $1.78
- BLRX $1.68
- Technical
- Relative Strength Index (RSI)
- PIII 35.62
- BLRX 25.94
- Support Level
- PIII $0.22
- BLRX $0.23
- Resistance Level
- PIII $0.23
- BLRX $0.56
- Average True Range (ATR)
- PIII 0.02
- BLRX 0.03
- MACD
- PIII 0.00
- BLRX 0.00
- Stochastic Oscillator
- PIII 26.62
- BLRX 11.82
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.